title: [Association of CD133 and endothelin-converting enzyme expressions with prognosis of non-small cell lung carcinoma].
abstract: OBJECTIVE
  To investigate the expression of tumor stem cell marker CD133 and endothelin-converting enzymes (ECE) in non-small cell lung carcinoma (NSCLC) and their association with NSCLC lymphoid metastasis.
  
  
  METHODS
  CD133 and ECE expressions was detected immunohistochemically in the specimens from 77 patients with NSCLC, and the association of CD133 and ECE expressions with the tumor size, histological type, differentiation, lymphoid metastasis, and prognosis of NSCLC was analyzed.
  
  
  RESULTS
  The positive expression rate of CD133 and ECE was 51.9% (40/77) and 45.5% (35/77) in these specimens, respectively. Both CD133 and ECE expressions were associated positively with lymphoid metastasis (r=0.246 and 0.339, P<0.05), and inversely with the survival time of the patients (P<0.05). CD133 and ECE expressions were not related to tumor size, histological type, and differentiation of the tumor (P>0.05). CD133 expression was associated positively with ECE expression in NSCLC (r=0.249, P<0.05).
  
  
  CONCLUSIONS
  CD133 and ECE expressions are associated with lymphoid metastasis and prognosis of NSCLC, and their overexpression often suggests unfavorable prognosis of NSCLC.
authors.affiliation: Department of Cardiothoracic Surgery, Second Affiliated Hospital of Sun Yat-sen University, Guangzhou 510120, China. zhhzhgd@163.com
authors.forename: Hui-zhong
authors.initials: HZ
authors.lastname: Zhang
authors.forename: Yi-ping
authors.initials: YP
authors.lastname: Wei
authors.forename: Mei
authors.initials: M
authors.lastname: Wang
authors.forename: Cheng
authors.initials: C
authors.lastname: Wu
authors.forename: Yan-qi
authors.initials: YQ
authors.lastname: Yang
authors.forename: Ju
authors.initials: J
authors.lastname: Chen
authors.forename: Yong-ke
authors.initials: YK
authors.lastname: Cao
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000096:biosynthesis*; D016282:Aspartic Acid Endopeptidases / Q000096:biosynthesis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism / Q000473:pathology*; D000072396:Endothelin-Converting Enzymes; D005260:Female; D006023:Glycoproteins / Q000096:biosynthesis*; D006801:Humans; D007150:Immunohistochemistry; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008666:Metalloendopeptidases / Q000096:biosynthesis*; D008875:Middle Aged; D010455:Peptides; D011379:Prognosis
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; D000072396:Endothelin-Converting Enzymes